2021 January 12th
Medical imaging company Oxipit announced partnership with Parasmed - a Nairobi based medical healthcare solutions distributor in Eastern Africa. With recent partnerships in Nigeria and strong foothold in Latin America, the new agreement is an important step towards creating a global, locally present network of Oxipit software distributors.
2020 August 24th
Teleradiologia de Colombia - a leading diagnostic imaging services provider in Latin America - is rolling out Oxipit AI solutions across its network. Oxipit AI suite will produce preliminary chest X-Ray reports and identify healthy patient images with no abnormalities, augmenting radiologist productivity and improving radiologist workflow. It marks the first Oxipit deployment in Colombia with more announcements in Latin America coming soon.
2020 August 17th
Oxipit has been awarded an “Eksperimentas” EU grant for researching and implementing innovative technologies for developing an Artificial Intelligence based patient screening tool to accurately identify healthy patients in chest X-ray images.
2020 July 22nd
Can we trust AI at the same level as a radiologist performing the same challenging task? In this interview we discuss AI machine learning model development, how can AI address radiologist subjectivity and the most challenging tasks in X-ray reporting automation.
2020 June 25th
Despite having a developed AI imaging provider ecosystem, the AI radiology reporting 'revolution' is an evolutionary tread towards clinical adoption. Oxipit COO Jogundas Armaitis shares his views on AI in radiology reporting steps and missteps.
2020 May 25th
Oxipit, creators of artificial intelligence based radiology imaging suite ChestEye, announces that the European Patent Office has approved their patent application. The innovation allows efficient use of high-resolution chest X-ray images for machine learning model training and is especially relevant for improving lung nodule detection.
2020 May 18th
Can AI-based diagnostics support medical institutions during the pandemic? Or is this yet another AI industry hype? Oxipit co-founder and chief operating officer Jogundas Armaitis shares the perspective of the company.
2020 March 5th
AI medical imaging company has received an Australian Register of Therapeutic Goods Class IIa medical device certificate for ChestEye AI imaging service. Medical device certification paves the way for clinical use of ChestEye in the Australian market. ChestEye imaging suite is already certified by the CE mark. Oxipit received CE certification last February, enabling clinical ChestEye deployment in 32 European countries.
2020 January 27th
The AI medical imaging company will showcase ChestEye Negative service at Arab Health 2020 conference in Dubai. ChestEye Negative produces preliminary reports for chest X-rays with no abnormality. The service aims to reduce the workload of radiologists, especially in clinical environments, where only a fraction of all studies features an abnormality. It also significantly simplifies large-scale medical screening projects.
2020 January 26th
EIT Health InnoStars presents a new episode of a series of talks with inspiring people in our community who develop innovative ideas. We ask about their journeys, while developing ideas, their professional career paths and motivations.
post thumbnail

Media About Us